B cell depletion therapy exacerbates murine primary biliary cirrhosis

Amy Dhirapong, Ana Lleo, Guo Xiang Yang, Koichi Tsuneyama, Robert Dunn, Marilyn Kehry, Thomas A. Packard, John C. Cambier, Fu-Tong Liu, Keith Lindor, Ross L. Coppel, Aftab A. Ansari, M. Eric Gershwin

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is considered a model autoimmune disease due to the clinical homogeneity of patients and the classic hallmark of antimitochondrial antibodies (AMAs). Indeed, the presence of AMAs represents the most highly directed and specific autoantibody in autoimmune diseases. However, the contribution of B cells to the pathogenesis of PBC is unclear. Therefore, although AMAs appear to interact with the biliary cell apotope and contribute to biliary pathology, there is no correlation of disease severity and titer of AMAs. The recent development of well-characterized monoclonal antibodies specific for the B cell populations, anti-CD20 and anti-CD79, and the development of a well-defined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the model to address the contribution of B cells in the pathogenesis of murine PBC. Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, anti-CD79, or isotype-matched control monoclonal antibody and followed for B cell development, the appearance of AMAs, liver pathology, and cytokine production. Results of the studies reported herein show that the in vivo depletion of B cells using either anti-CD20 or anti-CD79 led to the development of a more severe form of cholangitis than observed in control mice, which is in contrast with results from several other autoimmune models that have documented an important therapeutic role of B cell-specific depletion. Anti-CD20/CD79-treated mice had increased liver T cell infiltrates and higher levels of proinflammatory cytokines. Conclusion: Our results reflect a novel disease-protective role of B cells in PBC and suggest that B cell depletion therapy in humans with PBC should be approached with caution.

Original languageEnglish (US)
Pages (from-to)527-535
Number of pages9
JournalHepatology
Volume53
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Biliary Liver Cirrhosis
Cell- and Tissue-Based Therapy
B-Lymphocytes
Cholangitis
Antibodies
Autoimmune Diseases
Monoclonal Antibodies
Pathology
Cytokines
Liver
Xenobiotics
Autoantibodies
T-Lymphocytes

ASJC Scopus subject areas

  • Hepatology

Cite this

Dhirapong, A., Lleo, A., Yang, G. X., Tsuneyama, K., Dunn, R., Kehry, M., ... Gershwin, M. E. (2011). B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology, 53(2), 527-535. https://doi.org/10.1002/hep.24044

B cell depletion therapy exacerbates murine primary biliary cirrhosis. / Dhirapong, Amy; Lleo, Ana; Yang, Guo Xiang; Tsuneyama, Koichi; Dunn, Robert; Kehry, Marilyn; Packard, Thomas A.; Cambier, John C.; Liu, Fu-Tong; Lindor, Keith; Coppel, Ross L.; Ansari, Aftab A.; Gershwin, M. Eric.

In: Hepatology, Vol. 53, No. 2, 02.2011, p. 527-535.

Research output: Contribution to journalArticle

Dhirapong, A, Lleo, A, Yang, GX, Tsuneyama, K, Dunn, R, Kehry, M, Packard, TA, Cambier, JC, Liu, F-T, Lindor, K, Coppel, RL, Ansari, AA & Gershwin, ME 2011, 'B cell depletion therapy exacerbates murine primary biliary cirrhosis', Hepatology, vol. 53, no. 2, pp. 527-535. https://doi.org/10.1002/hep.24044
Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M et al. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology. 2011 Feb;53(2):527-535. https://doi.org/10.1002/hep.24044
Dhirapong, Amy ; Lleo, Ana ; Yang, Guo Xiang ; Tsuneyama, Koichi ; Dunn, Robert ; Kehry, Marilyn ; Packard, Thomas A. ; Cambier, John C. ; Liu, Fu-Tong ; Lindor, Keith ; Coppel, Ross L. ; Ansari, Aftab A. ; Gershwin, M. Eric. / B cell depletion therapy exacerbates murine primary biliary cirrhosis. In: Hepatology. 2011 ; Vol. 53, No. 2. pp. 527-535.
@article{58647637ac124edbb7024b57705572d4,
title = "B cell depletion therapy exacerbates murine primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is considered a model autoimmune disease due to the clinical homogeneity of patients and the classic hallmark of antimitochondrial antibodies (AMAs). Indeed, the presence of AMAs represents the most highly directed and specific autoantibody in autoimmune diseases. However, the contribution of B cells to the pathogenesis of PBC is unclear. Therefore, although AMAs appear to interact with the biliary cell apotope and contribute to biliary pathology, there is no correlation of disease severity and titer of AMAs. The recent development of well-characterized monoclonal antibodies specific for the B cell populations, anti-CD20 and anti-CD79, and the development of a well-defined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the model to address the contribution of B cells in the pathogenesis of murine PBC. Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, anti-CD79, or isotype-matched control monoclonal antibody and followed for B cell development, the appearance of AMAs, liver pathology, and cytokine production. Results of the studies reported herein show that the in vivo depletion of B cells using either anti-CD20 or anti-CD79 led to the development of a more severe form of cholangitis than observed in control mice, which is in contrast with results from several other autoimmune models that have documented an important therapeutic role of B cell-specific depletion. Anti-CD20/CD79-treated mice had increased liver T cell infiltrates and higher levels of proinflammatory cytokines. Conclusion: Our results reflect a novel disease-protective role of B cells in PBC and suggest that B cell depletion therapy in humans with PBC should be approached with caution.",
author = "Amy Dhirapong and Ana Lleo and Yang, {Guo Xiang} and Koichi Tsuneyama and Robert Dunn and Marilyn Kehry and Packard, {Thomas A.} and Cambier, {John C.} and Fu-Tong Liu and Keith Lindor and Coppel, {Ross L.} and Ansari, {Aftab A.} and Gershwin, {M. Eric}",
year = "2011",
month = "2",
doi = "10.1002/hep.24044",
language = "English (US)",
volume = "53",
pages = "527--535",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - B cell depletion therapy exacerbates murine primary biliary cirrhosis

AU - Dhirapong, Amy

AU - Lleo, Ana

AU - Yang, Guo Xiang

AU - Tsuneyama, Koichi

AU - Dunn, Robert

AU - Kehry, Marilyn

AU - Packard, Thomas A.

AU - Cambier, John C.

AU - Liu, Fu-Tong

AU - Lindor, Keith

AU - Coppel, Ross L.

AU - Ansari, Aftab A.

AU - Gershwin, M. Eric

PY - 2011/2

Y1 - 2011/2

N2 - Primary biliary cirrhosis (PBC) is considered a model autoimmune disease due to the clinical homogeneity of patients and the classic hallmark of antimitochondrial antibodies (AMAs). Indeed, the presence of AMAs represents the most highly directed and specific autoantibody in autoimmune diseases. However, the contribution of B cells to the pathogenesis of PBC is unclear. Therefore, although AMAs appear to interact with the biliary cell apotope and contribute to biliary pathology, there is no correlation of disease severity and titer of AMAs. The recent development of well-characterized monoclonal antibodies specific for the B cell populations, anti-CD20 and anti-CD79, and the development of a well-defined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the model to address the contribution of B cells in the pathogenesis of murine PBC. Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, anti-CD79, or isotype-matched control monoclonal antibody and followed for B cell development, the appearance of AMAs, liver pathology, and cytokine production. Results of the studies reported herein show that the in vivo depletion of B cells using either anti-CD20 or anti-CD79 led to the development of a more severe form of cholangitis than observed in control mice, which is in contrast with results from several other autoimmune models that have documented an important therapeutic role of B cell-specific depletion. Anti-CD20/CD79-treated mice had increased liver T cell infiltrates and higher levels of proinflammatory cytokines. Conclusion: Our results reflect a novel disease-protective role of B cells in PBC and suggest that B cell depletion therapy in humans with PBC should be approached with caution.

AB - Primary biliary cirrhosis (PBC) is considered a model autoimmune disease due to the clinical homogeneity of patients and the classic hallmark of antimitochondrial antibodies (AMAs). Indeed, the presence of AMAs represents the most highly directed and specific autoantibody in autoimmune diseases. However, the contribution of B cells to the pathogenesis of PBC is unclear. Therefore, although AMAs appear to interact with the biliary cell apotope and contribute to biliary pathology, there is no correlation of disease severity and titer of AMAs. The recent development of well-characterized monoclonal antibodies specific for the B cell populations, anti-CD20 and anti-CD79, and the development of a well-defined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the model to address the contribution of B cells in the pathogenesis of murine PBC. Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, anti-CD79, or isotype-matched control monoclonal antibody and followed for B cell development, the appearance of AMAs, liver pathology, and cytokine production. Results of the studies reported herein show that the in vivo depletion of B cells using either anti-CD20 or anti-CD79 led to the development of a more severe form of cholangitis than observed in control mice, which is in contrast with results from several other autoimmune models that have documented an important therapeutic role of B cell-specific depletion. Anti-CD20/CD79-treated mice had increased liver T cell infiltrates and higher levels of proinflammatory cytokines. Conclusion: Our results reflect a novel disease-protective role of B cells in PBC and suggest that B cell depletion therapy in humans with PBC should be approached with caution.

UR - http://www.scopus.com/inward/record.url?scp=79251485938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251485938&partnerID=8YFLogxK

U2 - 10.1002/hep.24044

DO - 10.1002/hep.24044

M3 - Article

C2 - 21274873

AN - SCOPUS:79251485938

VL - 53

SP - 527

EP - 535

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -